EPIX News and Press, ESSA Pharma Inc. From 02/13/23

ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Canada NewsWire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 13, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company"...

ESSA Pharma press release ( NASDAQ: EPIX ): Q1 GAAP EPS of -$0.15. At December 31, 2022, the Company had available cash reserves and short-term investments of $163.1 million reflecting the gross proceeds of the February 2021 financing of approximately $150.0 million and July 202...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022 Canada NewsWire Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study ...

Summary EPIX is targeting prostate cancer with its lead and only asset EPI-7386. While there's some rationale to the molecule's science, there's not a lot of convincing data yet. The company is also hurting for cash. ESSA Pharma ( EPIX ) is a Canadian developer of ther...

ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference Canada NewsWire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 2, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-st...

ESSA Pharma press release ( NASDAQ: EPIX ): FQ4 GAAP EPS of -$0.14 (vs. -$0.20 Y/Y). Net loss was $6.32M, compared to the year-ago $8.52M. For further details see: ESSA Pharma GAAP EPS of -$0.14

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022 Canada NewsWire SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, CANADA , Dec. 13, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the...

Summary The stock has pulled back from the 2x pop after the recent data of EPI-7386+Xtandi in post-chemotherapy metastatic castration-resistant prostate cancer, mCRPC. The efficacy of the EPI-7386+Xtandi combination in mCRPC beats that of currently approved drugs by a significant ...

ESSA Pharma to Participate in Two Upcoming Investor Conferences Canada NewsWire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 10, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical c...

Canadian biotech ESSA Pharma ( NASDAQ: EPIX ) shed ~26% pre-market Monday after announcing that Janssen Research and Development of Johnson & Johnson ( JNJ ) will no longer enroll patients in a Phase 1 trial for a drug combination involving its lead asset EPI-7386 in...